Targeting Serotonin Transporters in the Treatment of Juvenile and Adolescent Depression

Depression is a serious public health concern. Many patients are not effectively treated, but in children and adolescents this problem is compounded by limited pharmaceutical options. Currently, the Food and Drug Administration approves only two antidepressants for use in these young populations. Bo...

Full description

Bibliographic Details
Main Authors: Melodi A. Bowman, Lynette C. Daws
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-02-01
Series:Frontiers in Neuroscience
Subjects:
Online Access:https://www.frontiersin.org/article/10.3389/fnins.2019.00156/full
id doaj-aa11a0ebad00480b9880a68d121e177a
record_format Article
spelling doaj-aa11a0ebad00480b9880a68d121e177a2020-11-24T22:01:43ZengFrontiers Media S.A.Frontiers in Neuroscience1662-453X2019-02-011310.3389/fnins.2019.00156434875Targeting Serotonin Transporters in the Treatment of Juvenile and Adolescent DepressionMelodi A. Bowman0Lynette C. Daws1Lynette C. Daws2Department of Cellular and Integrative Physiology, University of Texas Health Science Center at San Antonio, San Antonio, TX, United StatesDepartment of Cellular and Integrative Physiology, University of Texas Health Science Center at San Antonio, San Antonio, TX, United StatesDepartment of Pharmacology, University of Texas Health Science Center at San Antonio, San Antonio, TX, United StatesDepression is a serious public health concern. Many patients are not effectively treated, but in children and adolescents this problem is compounded by limited pharmaceutical options. Currently, the Food and Drug Administration approves only two antidepressants for use in these young populations. Both are selective serotonin reuptake inhibitors (SSRIs). Compounding matters further, they are therapeutically less efficacious in children and adolescents than in adults. Here, we review clinical and preclinical literature describing the antidepressant efficacy of SSRIs in juveniles and adolescents. Since the high-affinity serotonin transporter (SERT) is the primary target of SSRIs, we then synthesize these reports with studies of SERT expression/function during juvenile and adolescent periods. Preclinical literature reveals some striking parallels with clinical studies, primary among them is that, like humans, juvenile and adolescent rodents show reduced antidepressant-like responses to SSRIs. These findings underscore the utility of preclinical assays designed to screen drugs for antidepressant efficacy across ages. There is general agreement that SERT expression/function is lower in juveniles and adolescents than in adults. It is well established that chronic SSRI treatment decreases SERT expression/function in adults, but strikingly, SERT expression/function in adolescents is increased following chronic treatment with SSRIs. Finally, we discuss a putative role for organic cation transporters and/or plasma membrane monoamine transporter in serotonergic homeostasis in juveniles and adolescents. Taken together, fundamental differences in SERT, and putatively in other transporters capable of serotonin clearance, may provide a mechanistic basis for the relative inefficiency of SSRIs to treat pediatric depression, relative to adults.https://www.frontiersin.org/article/10.3389/fnins.2019.00156/fullserotonintransportersdepressionantidepressantsdevelopmentchildren
collection DOAJ
language English
format Article
sources DOAJ
author Melodi A. Bowman
Lynette C. Daws
Lynette C. Daws
spellingShingle Melodi A. Bowman
Lynette C. Daws
Lynette C. Daws
Targeting Serotonin Transporters in the Treatment of Juvenile and Adolescent Depression
Frontiers in Neuroscience
serotonin
transporters
depression
antidepressants
development
children
author_facet Melodi A. Bowman
Lynette C. Daws
Lynette C. Daws
author_sort Melodi A. Bowman
title Targeting Serotonin Transporters in the Treatment of Juvenile and Adolescent Depression
title_short Targeting Serotonin Transporters in the Treatment of Juvenile and Adolescent Depression
title_full Targeting Serotonin Transporters in the Treatment of Juvenile and Adolescent Depression
title_fullStr Targeting Serotonin Transporters in the Treatment of Juvenile and Adolescent Depression
title_full_unstemmed Targeting Serotonin Transporters in the Treatment of Juvenile and Adolescent Depression
title_sort targeting serotonin transporters in the treatment of juvenile and adolescent depression
publisher Frontiers Media S.A.
series Frontiers in Neuroscience
issn 1662-453X
publishDate 2019-02-01
description Depression is a serious public health concern. Many patients are not effectively treated, but in children and adolescents this problem is compounded by limited pharmaceutical options. Currently, the Food and Drug Administration approves only two antidepressants for use in these young populations. Both are selective serotonin reuptake inhibitors (SSRIs). Compounding matters further, they are therapeutically less efficacious in children and adolescents than in adults. Here, we review clinical and preclinical literature describing the antidepressant efficacy of SSRIs in juveniles and adolescents. Since the high-affinity serotonin transporter (SERT) is the primary target of SSRIs, we then synthesize these reports with studies of SERT expression/function during juvenile and adolescent periods. Preclinical literature reveals some striking parallels with clinical studies, primary among them is that, like humans, juvenile and adolescent rodents show reduced antidepressant-like responses to SSRIs. These findings underscore the utility of preclinical assays designed to screen drugs for antidepressant efficacy across ages. There is general agreement that SERT expression/function is lower in juveniles and adolescents than in adults. It is well established that chronic SSRI treatment decreases SERT expression/function in adults, but strikingly, SERT expression/function in adolescents is increased following chronic treatment with SSRIs. Finally, we discuss a putative role for organic cation transporters and/or plasma membrane monoamine transporter in serotonergic homeostasis in juveniles and adolescents. Taken together, fundamental differences in SERT, and putatively in other transporters capable of serotonin clearance, may provide a mechanistic basis for the relative inefficiency of SSRIs to treat pediatric depression, relative to adults.
topic serotonin
transporters
depression
antidepressants
development
children
url https://www.frontiersin.org/article/10.3389/fnins.2019.00156/full
work_keys_str_mv AT melodiabowman targetingserotonintransportersinthetreatmentofjuvenileandadolescentdepression
AT lynettecdaws targetingserotonintransportersinthetreatmentofjuvenileandadolescentdepression
AT lynettecdaws targetingserotonintransportersinthetreatmentofjuvenileandadolescentdepression
_version_ 1725838932971618304